Skip to content

Brian J Mickey

5 papers in the library · 45 citations · publishing 2018-2025

Papers

Sort Most recent Most cited

Genetics of Response to ECT, TMS, Ketamine and Esketamine.

American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics June 17, 2025 Clio E Franklin, Murat Altinay, Kala Bailey et al. 2 citations

Treatment-resistant mood disorders are often managed with intensive interventions that include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), ketamine, and esketamine, but the role of genetics in clinical response to those interventions is yet to be clearly determined. Here, we review the current literature on the genetics of response to these treatment modalities. To...

DOI: 10.1002/ajmg.b.33038 (opens in new tab) Full text (opens in new tab) Esketamine Individualized treatment Tailored therapy Pharmacogenomics +12

Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.

Brain Stimulation 2024 Charles R Conway, Scott T Aaronson, Harold A Sackeim et al. 16 citations

RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention. To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs),...

DOI: 10.1016/j.brs.2024.03.016 (opens in new tab) Full text (opens in new tab) Esketamine Electroconvulsive therapy Recover trial Treatment-resistant depression trd +7

An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis

Brain Sciences December 22, 2023 Nicolas A. Nunez, Boney Joseph, Rakesh Kumar et al. 20 citations

Ketamine has shown rapid antidepressant and anti-suicidal effects in treatment-resistant depression (TRD) with single and serial intravenous (IV) infusions, but the effectiveness for depressive episodes of bipolar disorder is less clear. We conducted an updated systematic review and meta-analysis to appraise the current evidence on the efficacy and tolerability of ketamine/esketamine in bipolar...

DOI: 10.3390/brainsci13121672 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Treatment-resistant bipolar depression Metanalysis Systematic review +4

Propofol for treatment resistant depression: A randomized controlled trial

medRxiv September 15, 2023 Scott C. Tadler, Keith Jones, Carter Lybbert et al. 7 citations preprint

Background: Anesthetic agents including ketamine and nitrous oxide have shown antidepressant properties when appropriately dosed. Our recent open-label trial of propofol, an intravenous anesthetic known to elicit transient positive mood effects, suggested that it may also produce robust and durable antidepressant effects when administered at a high dose that elicits an electroencephalographic...

Emerging evidence for antidepressant actions of anesthetic agents.

Current Opinion in Anaesthesiology August 1, 2018 Scott C. Tadler, Brian J Mickey

After decades without substantial advances, multiple novel antidepressants show promise against treatment-resistant depression. Interestingly, many of these are anesthetics. The purpose of this review is to discuss the evidence for the antidepressant effects of ketamine, nitrous oxide, isoflurane and propofol and to consider potential clinical, administrative and research implications for...